1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26. PMID:
19937315
2. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36. PMID:
12811491
3. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 2011;29:185-90. PMID:
19898824
4. Sever N, Oskay U. An investigation of lower urinary tract symptoms in women aged 40 and over. Low Urin Tract Symptoms 2017;9:21-6. PMID:
28120450
6. Choo MS, Song C, Kim JH, Choi JB, Lee JY, Chung BS, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2005;174:201-4. PMID:
15947627
7. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:191-4. PMID:
16406907
8. Digesu GA, Khullar V, Panayi D, Calandrini M, Gannon M, Nicolini U. Should we explain lower urinary tract symptoms to patients? Neurourol Urodyn 2008;27:368-71. PMID:
17943984
10. Steers WD, Tuttle JB. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006;3:101-10. PMID:
16470209
11. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 2001;165:975-9. PMID:
11176525
12. Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, Cruz CD, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 2013;189:359-65. PMID:
23174241
13. Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 2010;12:e69-77. PMID:
20811555
14. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009;56:700-6. PMID:
18472208
16. Vijaya G, Cartwright R, Bhide A, Derpapas A, Fernando R, Khullar V. Reliability and validity of urinary nerve growth factor measurement in women with lower urinary tract symptoms. Neurourol Urodyn 2016;35:944-8. PMID:
26227147
17. Persson K, Sando JJ, Tuttle JB, Steers WD. Protein kinase C in cyclic stretch-induced nerve growth factor production by urinary tract smooth muscle cells. Am J Physiol 1995;269(4 Pt 1):C1018-24. PMID:
7485441
18. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 2010;106:1681-5. PMID:
19751258
19. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 2008;102:1440-4. PMID:
18489524
22. Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J Formos Med Assoc 2010;109:862-78. PMID:
21195884
23. Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J 2013;24:1065-72. PMID:
23314226
24. Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011;30:1227-41. PMID:
21520250
25. Sariola H, Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 2003;116(Pt 19):3855-62. PMID:
12953054
27. Gamper M, Moser R, Viereck V. Have we been led astray by the NGF biomarker data? Neurourol Urodyn 2017;36:203-4. PMID:
26384156